| 利用者成果(英) |
|
19670
Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, Trinh D, Hebbert A, Smith CR, Kulyk S, Lawson JD, He L, Hover LD, Fernandez-Banet J, Hallin J, Vanderpool D, Briere DM, Blaj A, Marx MA, Rodon J, Offin M, Arbour KC, Johnson ML, Kwiatkowski DJ, Jänne PA, Haddox CL, Papadopoulos KP, Henry JT, Leventakos K, Christensen JG, Shazer R, Olson P.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Cancer Discov
2023
13(11):2412-2431
PubMed ID: 37552839
DOI: 10.1158/2159-8290.CD-23-0669
|
|
21465
Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M, Kottarathil T, Piquet M, Cao Y, Martinuzzi-Duboc L, Buhles A, Alder F, Mannino S, Tordella L, Sansregret L, Maira SM, Graus Porta D, Fedele C, Brachmann SM.
CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer.
Cancer Res
2023
PubMed ID: 37934115
DOI: 10.1158/0008-5472.CAN-23-1127
|
|
17631
Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy SR, Gainor JF, Rajan AP, Nieblas-Bedolla E, Burns AC, Hallin J, Olson P, Christensen JG, Kurz SC, Brastianos PK, Wakimoto H.
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Clin Cancer Res
2022
28(15):3318-3328
PubMed ID: 35404402
DOI: 10.1158/1078-0432.CCR-22-0383
|
|
20534
Smith CR, Aranda R, Bobinski TP, Briere DM, Burns AC, Christensen JG, Clarine J, Engstrom LD, Gunn RJ, Ivetac A, Jean-Baptiste R, Ketcham JM, Kobayashi M, Kuehler J, Kulyk S, Lawson JD, Moya K, Olson P, Rahbaek L, Thomas NC, Wang X, Waters LM, Marx MA.
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.
J Med Chem
2022
PubMed ID: 35041419
DOI: 10.1021/acs.jmedchem.1c01900
|
|
20913
Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM.
PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.
Br J Cancer
2022
PubMed ID: 36319849
DOI: 10.1038/s41416-022-02032-w
|
|
16801
Minegishi K, Dobashi Y, Tsubochi H, Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y, Endo S.
TFF-1 Functions to Suppress Multiple Phenotypes Associated with Lung Cancer Progression
Onco Targets Ther
2021
14:4761-4777
PubMed ID: 34531663
DOI: 10.2147/OTT.S322697
|
|
13304
Colombo M, Marabese M, Vargiu G, Broggini M, Caiola E.
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.
Front Oncol
2020
PubMed ID: 33194590
DOI: 10.3389/fonc.2020.532292
|
|
13773
Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites
Cancer Sci
2020
111(2):667-678
PubMed ID: 31828882
DOI: 10.1111/cas.14278
|
|
13841
Eguchi R, Wakabayashi I.
HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer
Oncol Rep
2020
44(1):14-28
PubMed ID: 32319650
DOI: 10.3892/or.2020.7580
|
|
13925
Iezzi A, Caiola E, Colombo M, Marabese M, Broggini M.
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
Am J Cancer Res
2020
10(12):4488-4497
PubMed ID: 33415013
|
|
15895
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG.
The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Cancer Discov
2020
10(1):54-71
PubMed ID: 31658955
DOI: 10.1158/2159-8290.CD-19-1167
|
|
11496
Miyake N, Chikumi H, Yamaguchi K, Takata M, Takata M, Okada K, Kitaura T, Nakamoto M, Yamasaki A.
Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness.
Yonago Acta Med
2019
PubMed ID: 30962749
DOI: 10.33160/yam.2019.03.012
|
|
4280
Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M.
Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Molecules
2018
PubMed ID: 30126206
DOI: 10.3390/molecules23082071
|
|
7006
Iida K, Sakai R, Yokoyama S, Kobayashi N, Togo S, Yoshikawa HY, Rawangkan A, Namiki K, Suganuma M.
Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
Sci Rep
2017
7:17770
PubMed ID: 29259259
DOI: 10.1038/s41598-017-18120-4
|
|
14222
Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T.
Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC
Mol Cancer Res
2017
15(10):1354-1365
PubMed ID: 28698358
DOI: 10.1158/1541-7786.MCR-17-0191
|
|
14130
Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM.
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
Cell Rep
2016
15(3):574-587
PubMed ID: 27068473
DOI: 10.1016/j.celrep.2016.03.043
|
|
7462
Tomita T, Ieguchi K, Sawamura T, Maru Y.
Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor.
PLoS ONE
2015
10:e0118835
PubMed ID: 25738827
DOI: 10.1371/journal.pone.0118835
|
|
15129
Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y.
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity
J Med Chem
2015
58(4):1760-75
PubMed ID: 25625617
DOI: 10.1021/jm501599u
|
|
9106
Seo SK, Hwang CS, Choe TB, Hong SI, Yi JY, Hwang SG, Lee HG, Oh ST, Lee YH, Park IC.
Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation
Oncotarget
2015
6(28):26528-40
PubMed ID: 25605253
DOI: 10.18632/oncotarget.3100
|
|
5833
Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, Yano H, Sannomiya K, Goji T, Miyamoto H, Okahisa T, Mikasa H, Wada S, Iwata M, Takayama T.
High antitumor activity of pladienolide B and its derivative in gastric cancer.
Cancer Sci
2014
105(1):110-6
PubMed ID: 24635824
DOI: 10.1111/cas.12317
|
|
15715
Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H.
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma
PLoS One
2011
6(9):e25301
PubMed ID: 21966491
DOI: 10.1371/journal.pone.0025301
|
|
16553
Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H.
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer
J Transl Med
2011
9:191
PubMed ID: 22053850
DOI: 10.1186/1479-5876-9-191
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト